<style>
/* 只针对 Research 正文做一点排版，不动全局样式 */

/* 主体容器：宽度与原页面相近，略微居中 */
.lab-container {
  max-width: 820px;
  margin: 10px auto 40px auto;
  padding: 0 10px;
}

/* 每个研究方向一个小模块，边框很轻，不抢眼 */
.lab-section {
  background: #ffffff;
  border-radius: 6px;
  padding: 14px 16px;
  margin-bottom: 16px;
  border-left: 3px solid #8c1515;   /* 深红细边 */
}

/* 标题：略加粗，字号比正文大一点即可 */
.lab-section h2 {
  font-size: 20px;
  margin: 0 0 6px 0;
  color: #222;
  font-weight: 600;
}

/* 正文：保持和主题接近的行距与字号 */
.lab-section p {
  font-size: 15px;
  line-height: 1.6;
  color: #333;
  margin: 0;
}
</style>

<div class="lab-container">

  <div class="lab-section">
    <h2>Virus-driven immune remodeling in transplantation and cellular therapies</h2>
    <p>
      We study how CMV, EBV, and other viral exposures reshape immune reconstitution after HSCT, CAR-T therapy, and other advanced cellular treatments. Using longitudinal CyTOF and single-cell sequencing, we map immune trajectories and identify signatures linked to toxicity, relapse, and infection. Computational models integrate viral kinetics with immune dynamics to guide precision monitoring and therapeutic decision-making.
    </p>
  </div>

  <div class="lab-section">
    <h2>Precision immunology and immunotherapy in acute myeloid leukemia</h2>
    <p>
      AML serves as a key disease model to understand therapy-induced immune remodeling. We investigate how induction regimens such as HAV, antigen drift, and the immune microenvironment shape AML outcomes. We also develop and evaluate AML-directed immunotherapies—including CAR-T cells, vaccines, and viral-antigen–driven immunogenic strategies—to enhance antileukemic immunity and improve long-term survival.
    </p>
  </div>

  <div class="lab-section">
    <h2>Integrating HSCT and CAR-T with multimodal immunotherapies</h2>
    <p>
      We integrate HSCT, CAR-T, and additional immune-based approaches to develop multimodal therapeutic strategies aimed at improving long-term disease control in hematologic malignancies.
    </p>
  </div>

</div>
